Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SPCOO)
| ADC Name |
laventatug tivedotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
laventatug tivedotin; BRY812
Click to Show/Hide
|
|||||
| Organization |
Biorui Biotech (Originator)
|
|||||
| Drug Status |
Phase 2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
~4.1
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Laventatug
|
Antibody Info | ||||
| Antigen Name |
Zinc transporter ZIP6 (SLC39A6)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
BrAc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
tivedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Endometrial cancer |
1 Trials
|